Hybrid and tandem expression of neisseria proteins

FIELD: chemistry, immonology.

SUBSTANCE: hybrid protein includes 936 protein sequence from Neisseria meningitides or protein with sequence identical to the mentioned protein sequence by 90% or more, and 741 protein sequence from Neisseria meningitides or protein with sequence identical to the mentioned protein sequence by 90% or more. The sequences can be linked by N- and/or C-end to histidine labels, with or without a linker. Linker is selected out of group of polyglycine linker, histidine labels and GSGGGG linker. A nucleic acid encoding this protein is displayed. Invention also claims composition for treatment and/or prevention of disease caused by Neisseria meningitides bacterium, based on hybrid protein and one or more proteins of the following group: 287, 741, ORF46.1, 961, NH2-A-[X-L-]n-B-COOH, where n=2, X1=287, and X2 is selected out group of: 953, 919, 961, 741. Invention claims application of composition in production of medicine for treatment of disease caused by Neisseria.

EFFECT: efficient treatment and prevention of disease.

13 cl, 5 dwg, 28 tbl, 1 ex

 

The text descriptions are given in facsimile form.

1. A hybrid protein having the formula

NH2-A-[-X-L-]n-B-COOH,

where L is an optional linker aminokislot the second sequence, having 20 or less amino acids, and L is chosen from the group consisting of polyglycidyl the linker his-tag labels and GSGGGG linker, And indicates an optional N-terminal amino acid sequence, with 40 or fewer amino acids, and is chosen from the group consisting of his-tag labels and the residue is methionine, indicates an optional C-terminal amino acid sequence, with 40 or fewer amino acids, with mean his-tag labels, and n=2, X includes X1and X2where X1represents the sequence of the protein 936 or polypeptide having an identity of 90% or more with this sequence from Neisseria meningitidis, and X2represents the sequence of the protein 741 or polypeptide having an identity of 90% or more with this sequence of Neisseria meningitidis and the hybrid protein has an immunological activity against Neisseria meningitidis.

2. A hybrid protein according to claim 1, in which X1comes from a strain of Neisseria meningitidis 2996.

3. A hybrid protein according to claim 1, in which X2comes from a strain of Neisseria meningitidis MS.

4. A hybrid protein according to claim 1, having the sequence mentioned in SEQ ID 30.

5. Nucleic acid encoding a protein according to any one of claims 1 to 4.

6. Composition for prevention and/or treatment of diseases caused by Neisseria meningitidis containing protein according to any ISP-4, and one or more of the following proteins:

(1) 287,

(2) 741,

(3) ORF46.1,

(4) 961,

(5) NH2-A-[-X-L-]n-B-COOH, where n=2, X1=287, X2=953,

(6) NH2-A-[-X-L-]n-B-COOH, where n=2, X1=287, X2=919,

(7) NH2-A-[-X-L-]n-B-COOH, where n=2, X1=287, X2=961,

(8) NH2-A-[-X-L-]n-B-COOH, where n=2, X1=287, X2=741.

7. The composition according to claim 6, containing proteins (4) and (5).

8. The composition according to claim 7, where the protein (4) contains SEQ ID 31, and protein (5) contains 28 or SEQ ID SEQ ID 29.

9. Composition according to any one of p-8, optionally containing

protein antigen N.meningitidis,

preparation of outer membrane vesicles (OMV) N.meningitidis and/or

charigny antigen N.meningitidis.

10. Composition according to any one of p-9, optionally containing pharmaceutically acceptable carrier.

11. The composition of claim 10 for use as a medicine.

12. The use of a composition of claim 10 for the manufacture of a medicinal product for the treatment of a disease caused by Neisseria.

13. The application indicated in paragraph 12, where the disease is a bacterial meningitis.



 

Same patents:

FIELD: biology, gene engineering.

SUBSTANCE: invention can be used for marking of biological objects. The molecule of nucleic acid which codes the fluorescing protein chosen from fluorescing proteins of representatives of kind Phialidium sp. are both suborder Anthomedusae and fluorescing mutants of the specified proteins allocated. By means of the allocated nucleic acid are obtained cloning and expressing vectors, fluorescing protein, the protein of merge capable to fluorescence, and also the expressing cartridge. The cell and the stable cellular line, containing such express ionic cartridge, produce fluorescing fiber. The fluorescing protein, nucleic acid coding it and the express ionic genetic designs containing this nucleic acid, use in a set for marking of a biological molecule. Fluorescent protein is also used in methods of marking of a biological molecule, a cell or a cellular organella.

EFFECT: invention application allows dilating an arsenal of agents for marking of biological objects.

13 cl, 12 dwg,12 ex

FIELD: chemistry.

SUBSTANCE: invention relates to field of biotechnology, namely to genetic engineering. New interferon-binding proteins, which modulate activity of different interferon-α subtypes, as well as interferon-β activity, are obtained. Described is cloning of DNA fragment, which codes interferon-α/β, binding protein IFNAB-BPI, and expression of obtained DNA fragment in host-cells both with formation of respective polypeptide and in form of fused proteins. Practical application of obtained proteins as components of pharmaceutical compositions for inhibiting activity of IFN-α or IFN-β is suggested. Invention can be applied in medicine for inhibiting undesirable impact of IFN-α or IFN-β.

EFFECT: obtaining new interferon-binding proteins, which can find application in medicine for inhibiting undesirable impact of IFN-α or IFN-β.

13 cl, 10 dwg, 6 tbl, 17 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology and immunology. Claimed is therapeutically active fused protein with reduced immunogenicity. Protein consists of two proteins derived from human proteins connected through the fusion region. Connective region, which covers or surrounds fusion region within the limits from 1 to 25 amino acid residues, contains modification, which removes T-cell epitope, in norm absent in humans. Claimed is application of fused protein for obtaining pharmaceutical composition for tumour treatment. Claimed is nucleic acid coding fused protein. Method of reduction of fused protein immunogenicity by introduction of substitutes of corresponding amino acids is described. Application of the invention allows reducing ability of connective epitope of therapeutically active fused protein to bind with molecules of the main complex of hystocompatibility (MHC) of class II, which finally reduces interaction of epitope with receptors of T-cells and can find application in medicine for prevention of immunological disorders arising with introduction of therapeutically active protein non-modified in connective region.

EFFECT: reduction of interaction of epitope with receptors of T-cells, which can find application in medicine for prevention of immunological disorders arising with introduction of therapeutically active protein non-modified in connective region.

23 cl, 12 ex

FIELD: medicine.

SUBSTANCE: invention concerns genetic engineering, biotechnology, immunology and medicine and can be applied in obtaining antitumoral vaccine and melanoma treatment. Vaccine compositions are based on heat shock proteins and antigen peptides for treatment of tumor disease, the said compositions containing hybrid protein consisting of heat shock HSP70 family protein and one of specific melanoma MAGE peptides (A1, A2, A3) or gp 100, as well as suitable pharmaceutical carrier. The invention also claims a method for obtaining the said hybrid proteins by gene expression in synthetic recombinant vectors in producer strains of E coli BL21 (DE3) cells.

EFFECT: improved immunising power.

3 cl, 4 ex, 1 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: essence of the invention lies in a composition which, after introduction to an individual, is capable of inducing a humoral immune response at the given individual the humoral immune response performing bactericidal effect against two or three of supervirulent rows of generations A4, ET5 and a number of generations of the 3rd serogroup in N.meningitidis. of an external membrane. Five albuminous antigens are used, i.e. (1) protein "NadA"; (2) protein "741"; (3) protein "936"; (4) protein of "953" and (5) protein "287".

EFFECT: development of a vaccine against two or more rows of supervirulent meningococcus generations.

29 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to genetic engineering and biotechnology and can be used for labelling of proteins, cells and organisms. Substitutes added to nucleic acid Aequorea coerulescens, coding colourless GFP-like protein acGFP is considered as means of production of nucleic acid coding fluorescent protein. Expression cassette containing this nucleic acid under regulatory elements control provides in-cell biosynthesis of fluorescent protein. This genetic structure is used for production of transgenic organism and cell producing fluorescent protein, coded by specified nucleic acid. This fluorescent protein is applied in methods for labelling of cells, intracellular structure and protein, as well as for promotor transcriptional activity registration.

EFFECT: invention application ensures widen range of labelling means used in biochemistry, molecular biology and medical diagnostics.

11 cl, 34 dwg, 2 ex

FIELD: organic chemistry, genetics.

SUBSTANCE: invention refers to genetic engineering, specifically to production of proinsulin Glargin and can be applied for production of medicines of new generation used for insulin-dependent pancreatic diabetes. Designed recombinant plasmid DNA pGG-1 codes hybrid protein with amino acid sequence of proinsulin Glargin, where sequence of domain B of protein A Staphylococcus aureus is connected through peptide linker His6GlySerArg with amino acid sequence of proinsulin Glargin having molecular weight 3,3 MDa (5051 "п.о"), containing HindIII/BamHI-fragment of plasmide pPINS07, including hybride tac-promoter, gene of β-lactamase ("bla"), replication origin area (ori), terminator of ribosomal operon E. coli transcription, nucleotide sequence coding amino acid sequence of domain B of protein A Staphylococcus aureus, connected to nucleotide sequence coding peptide His6GlySerArg, HindIII/BamHI-fragment (271 "п.о"), coding proinsulin Glargin; unique restriction sites with following coordinates: EcoRI - 1, NcoI - 217, BamHI - 221, PstI - 342 and 417, HindIII - 492, SalGI - 4513, ClaI - 4792. Bacteria Escherichia coli BL21 are transformed with plasmide pGG-1 that resulted in strains Escherichia coli BGG18, producer of hybride polypeptide containing amino acid sequence of proinsulin Glargin. Invention enables to produce insulin Glargin with high yield and applying simplified technology.

EFFECT: production of insulin Glargin with high yield and applying simplified technology.

2 cl, 4 dwg, 4 ex

FIELD: technological processess.

SUBSTANCE: oligomeric polypeptide dimmers include ligand-binding leptyne domains. Domains are connected by means of flexible polypeptide linker molecules. Linker molecules might possibly include sites of sensitivity to proteases.

EFFECT: releases biologically active cytokines when injecting to human being or animal.

31 cl, 13 dwg

FIELD: genetic engineering, medicine.

SUBSTANCE: invention proposes chimeric protein (ANTH1) consisting of a sequence corresponding to 60 amino acids of N-terminal region of interleukin-2 and extracellular moiety of N-terminal moiety of human gamma-interferon alpha-chain that are bound each with other by peptide Ala-His-Met-Met. Protein ANTH1 possesses capacity to inhibit biological activity of gamma-interferon and/or interleukin-2 and therefore it can be used in preparing drugs designated for treatment of diseases mediated by activity of interleukin-2, gamma-interferon or both these cytokines, in particular, in treatment of cerebrospinal sclerosis, erythematosus lupus, proliferative arthritis, diabetes mellitus and others. Invention can be used in medical-biological industry.

EFFECT: valuable medicinal and biological properties of protein.

13 cl, 1 tbl, 10 dwg, 11 ex

FIELD: biotechnology, immunology.

SUBSTANCE: disclosed are variants of chimerical anti-IL-6 antibodies based on mice CLB-8 antibody. Each antibody contains constant region from one or more human antibodies. Described are variants of nuclear acids encoding anti-IL-6 antibody, vectors and host cells. Developed is method for production of anti-IL-6 antibody by using nuclear acid or vector. Described are variants of composition for application in method for modulation of malignant disease or immune disorder mediated with IL-6. Developed is method for treatment or modulation of malignant disease or immune disorder mediated with IL-6.

EFFECT: variant of chimerical anti-IL-6 antibody with high affinity of mice anti-IL-6 antibody and reduced immonogenicity.

26 cl, 16 dwg, 1 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns biotechnology. The protein from N.meningitidis, named NMB1125, representing antigen, capable to cause the protective response against the infections caused by bacteria from sort Neisseria in an organism of the recipient, and having the established amino-acid sequence is described. A gene coding described protein is presented. The present invention can be used for obtaining the compositions possessing an expanded immune range and, thereby, to dilate a range of their action against various pathogens.

EFFECT: expansion of an action range of a preparation against various pathogens.

12 cl, 13 ex, 17 dwg, 3 tbl

FIELD: technological processes; biotechnologies.

SUBSTANCE: protein from N. meningitides is described, named NMB0928, which represents antigen that is capable to generate protective response in recipient body against infections caused by bacteria from Neisseria genus, and which has preset amino-acid sequence. Gen is presented that codes described protein.

EFFECT: expansion of effective range of action against different pathogens.

12 cl, 13 ex, 17 dwg, 3 tbl

FIELD: medicine.

SUBSTANCE: essence of the invention lies in a composition which, after introduction to an individual, is capable of inducing a humoral immune response at the given individual the humoral immune response performing bactericidal effect against two or three of supervirulent rows of generations A4, ET5 and a number of generations of the 3rd serogroup in N.meningitidis. of an external membrane. Five albuminous antigens are used, i.e. (1) protein "NadA"; (2) protein "741"; (3) protein "936"; (4) protein of "953" and (5) protein "287".

EFFECT: development of a vaccine against two or more rows of supervirulent meningococcus generations.

29 cl, 1 tbl

FIELD: biotechnology, microbiology, immunology.

SUBSTANCE: invention proposes peptide from N. meningitides eliciting a sequence SEQ ID NO:10 that is used in treatment or diagnosis. Also, invention proposes polynucleotide encoding this peptide, a host-cell expressing peptide, microorganism, vaccine and antibody showing specificity to peptide proposed. Invention can be used in medicine.

EFFECT: valuable medicinal properties of peptide.

16 cl, 2 tbl

FIELD: biotechnology, microbiology.

SUBSTANCE: invention relates, in particular, to antigene peptide sequences from microorganism Neisseria meningitides and N. gonorrhoeae. Described proteins comprise fragment of one or more Neisseria proteins with the definite amino acid sequence and the definite amount of amino acid residues (amino acid sequences are given in the invention description). Also, invention describes nucleic acids encoding indicated proteins and their using in preparing a medicinal agent used in treatment and prophylaxis of infection caused by neisseria. Use of protein and nucleic acids as components of the diagnostic reagent for detection of neisseria or antibodies raised to neisseria is proposed. Invention describes the immunogenic composition based on protein or nucleic acids for preparing specific antibodies and its using in treatment of the corresponding infection. Using the invention provides preparing protein vaccines showing effectiveness with respect to N. meningitidis B.

EFFECT: improved preparing method, valuable medicinal properties of peptides.

19 cl, 1 tbl, 1 ex

FIELD: biotechnology, microbiology, medicine.

SUBSTANCE: invention represents group of Neisseria proteins eliciting antigen properties. Protein eliciting antigen properties comprises fragment of protein ORF 40 (amino acid sequence of ORF 40 is given in the invention claim) that involves 7 or more conservative amino acids arranging in succession. Proteins as components of proteins in the claimed group are used as a medicinal agent or for it manufacturing for treatment and prophylaxis of infection caused by Neisseria, and for manufacturing the diagnostic preparation. Invention relates also nucleic acid encoding the Neisseria protein. Nucleic acid is used as the protein. Applying the invention provides the maximal recognition and reactivity between strains of Neisseria. Invention can be used in manufacturing curative-prophylactic preparations with respect to Neisseria meningitides.

EFFECT: valuable biological and medicinal properties of antigen.

27 cl, 51 dwg, 10 ex

FIELD: biotechnology, medicine, infectious diseases, medicinal microbiology.

SUBSTANCE: invention relates to a composition designated for treatment and prophylaxis of infections caused by Neisseria microorganism that comprises the following components: (a) protein with amino acid sequence similar by 65% and above with the natural Neisseria protein of a single species (the first group of amino acid sequences is given in the text) and/or its fragment consisting of 10 and more amino acids and eliciting antigen properties; (b) the second protein with amino acid sequence similar by 65% and above with the natural Neisseria protein of another species (the second group of amino acid sequences with even numbers is given in the text), and/or its fragment consisting of 10 or more amino acids and eliciting antigen properties; in particular, the second protein represents NspA. The composition comprises additionally adjuvant. The composition is used both a medicinal agent and for manufacturing the medicinal agent. Applying the invention provides enhancing the effectiveness of prophylaxis or treatment due to the universal effect of the composition (vaccine). Invention can be used in medicine for treatment of infections.

EFFECT: valuable medicinal properties of composition.

8 cl, 137 dwg, 5 tbl, 12 ex

The invention relates to biotechnology and is a purified and isolated nucleic acid molecule that encodes a protein of the bacteria Moraxella catarrhalis or immunogenic fragment transferrin receptor, as well as a method of obtaining a recombinant protein transferrin receptor

FIELD: chemistry.

SUBSTANCE: invention concerns compounds of formula (I) and their pharmaceutically acceptable salts as β-lactamase inhibitors, method of their production, pharmaceutical composition based on them, and methods of treatment involving the claimed compounds. In the general formula (I) one of A and B is hydrogen, while the other is optionally substituted condensed bicyclic heteroaryl group; if aromatic ring part of bicyclic heteroaryl group is imidazole, non-aromatic ring part does not include S atom adjacent to head carbon atom of bridge group; X is S; R5 is H, C1-C6-alkyl or C5-C6-cycloalkyl; or its pharmaceutically acceptable salt where bicyclic heteroaryl group is (1-A) , where one of Z1, Z2 and Z3 is independently S, while the others are CR2 or S, if one of Z1-Z3 is carbon and is linked to the rest of molecule; W1, W2 and W3 are independently CR4R4, S, O or N-R1, if it does not form S-S, O-O, or S-O link with saturated ring system; t=1-4; R1 is H, C1-C6-alkyl, C5-C7-cycloalkyl, -C=O-aryl, -C=O(C1-C6)-alkyl, -C=O(C5-C6)-cycloalkyl, aryl-C1-C6-alkyl, optionally substituted C1-C6-alkoxy; heteroalkyl- C1-C6-alkyl or C=O(heteroaryl), where heteroaryl is 6-member ring containing 1 nitrogen atom, R2 is hydrogen, C1-C6-alkyl, R4 ir H, C1-C6-alkyl.

EFFECT: efficient application in bacterial infection treatment.

29 cl, 3 tbl, 58 ex

Up!